10x Genomics (TXG) EV/EBIT: History & Chart

10x Genomics, Inc.(TXG)

Biotechnology · Pleasanton, CA

$83.00-14.74 (-15.09%)

Delayed quote: Oct 6, 2026, 2:25 PM EDT

About 10x Genomics, Inc.

Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.

Pleasanton, CA

1,178 employees

www.10xgenomics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Serge Saxonov

View full financials

NAME	MARKET CAP	EV/EBIT RATIO	TTM	3Y	5Y
10x Genomics, Inc. (TXG)	$10.54B	N/A	N/A	N/A	N/A
Universal Health Services, Inc. (UHS)vs ›	$10.69B	7.68x	8.63x	11.13x	11.58x
Twist Bioscience Corporation (TWST)vs ›	$10.72B	N/A	N/A	N/A	N/A
Globus Medical, Inc. (GMED)vs ›	$10.37B	15.27x	24.55x	55.38x	46.15x
ImmunityBio, Inc. (IBRX)vs ›	$10.38B	N/A	N/A	N/A	N/A
BioMarin Pharmaceutical Inc. (BMRN)vs ›	$10.87B	51.95x	25.50x	52.86x	123.66x
Align Technology, Inc. (ALGN)vs ›	$10.14B	16.60x	19.50x	23.74x	27.91x
Molina Healthcare, Inc. (MOH)vs ›	$10.13B	30.73x	14.47x	11.64x	12.65x
The Cooper Companies, Inc. (COO)vs ›	$10.97B	24.52x	26.33x	30.62x	34.46x
The Ensign Group, Inc. (ENSG)vs ›	$10.08B	25.81x	30.24x	30.29x	26.96x

NAME

MARKET CAP

EV/EBIT RATIO

TTM

10x Genomics, Inc. (TXG)

$10.54B

N/A

Universal Health Services, Inc. (UHS)vs ›

$10.69B

7.68x

8.63x

11.13x